C4 Therapeutics reported second quarter 2026 financial results on August 11, 2026. Total revenue was $6.6 million, driven by a $20 million upfront payment from a new collaboration with Roche for degrader-antibody conjugate research. The company raised approximately $33.5 million in net proceeds through its at-the-market equity program. R&D expense decreased to $24.5 million and G&A expense fell to $8.6 million, resulting in a net loss of $23.6 million, or $0.18 per share. Cash, cash equivalents, and marketable securities totaled $300.4 million as of June 30, 2026, which management expects will fund operations through the end of 2028. The company operates in the biopharmaceutical industry, focusing on targeted protein degradation therapies for multiple myeloma.

On June 24, 2026, C4 Therapeutics held its Annual Meeting of Stockholders. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors, approved executive compensation in a non-binding advisory vote, and ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026. Additionally, stockholders approved an amendment to the 2020 Stock Option and Incentive Plan to include outstanding pre-funded warrants in the calculation of the evergreen provision's share increase. The company is a biotechnology firm that develops targeted protein degradation therapies.

C4 Therapeutics, Inc. announced the release of further analysis from its fully enrolled Phase 1 trial of cemsidomide, an oral IKZF1/3 degrader, used in combination with dexamethasone for treating relapsed/refractory multiple myeloma. This data will be presented at the European Hematology Association 2026 Congress. C4 Therapeutics, Inc. is a biotechnology company focused on ability-based protein degradation.</div>